Half-Year 2022 Financial and Clinical Trials Update
HY 2022: Non-core and IFRS income
Decrease in non-core operating expenses driven by lower amortisation of
intangible assets due to Esbriet and lower costs for global restructuring plans
2021
2022
Change in %
CHFM
CHFM
CHFM
CHF
CER
Core operating profit
11,652
12,668
1,017
+9
+9
Global restructuring plans
-511
-265
246
Amortisation of intangible assets
-830
-468
362
Impairment of intangible assets¹
-165
-423
-258
M&A and alliance transactions
-37
17
54
Legal & Environmental²
-32
19
51
Total non-core operating items
-1,575
-1,120
455
IFRS Operating profit
10,077
11,547
1,469
+15
+15
Total financial result & taxes
-1,861
-2,386
-525
IFRS net income
8,216
9,161
944
+12
+12
CER = Constant Exchange Rates; 1 incl. goodwill; 2 incl. pension plan settlements
Roche
61View entire presentation